Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells.

ABSTRACT: Molecular targeted therapy using a drug that suppresses the growth and spread of cancer cells via inhibition of a specific protein is a foundation of precision medicine and treatment. High expression of the proto-oncogene Bcl-3 promotes the proliferation and metastasis of cancer cells originating from tissues such as the colon, prostate, breast, and skin. The development of novel drugs targeting Bcl-3 alone or in combination with other therapies can cure these patients or prolong their survival. As a proof of concept, in the present study, we focused on metastatic melanoma as a model system. High-throughput screening and in vitro experiments identified BCL3ANT as a lead molecule that could interfere with Bcl-3-mediated cyclin D1 expression and cell proliferation and migration in melanoma.

SUBMITTER: Saamarthy K 

PROVIDER: S-EPMC10795364 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature